Cognition Therapeutics, Inc. CGTX 深 滬
交易中 08-20 11:38:46 美东时间
1.8701
+0.200
+11.98%
華盛通- 最 高1.9181
- 今 開1.76
- 成交量 372.86万股
- 最 低 1.6801
- 昨 收 1.67
- 總市值 1.16亿
- 52周最高 1.97
- 市盈率 靜 --
- 換手率 6.01%
- 52周最低 0.2223
- 委 比 0.22%
- 總股本 6199.30万
- 歷史最高 13.80
- 量 比 0.65
- 振 幅 14.25%
- 歷史最低 0.2223
- 每 手 1
- 風險率 0.20%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股牛股 | TeraWulf股价飙涨近60%，公司与谷歌达成重要合作；MIAX上市首日飙升33%
TeraWulf股价飙涨近60%，公司与谷歌达成重要合作；美国交易所运营商迈阿密国际控股上市首日飙升33%；Q2业绩强劲，黄金股Galiano Gold涨超22%>>
08-15 14:25
Cognition Therapeutics Surges 30% Pre-Market After FDA Backs Phase 3 Trial Design For Alzheimer's Drug
Cognition Therapeutics shares rose 30% pre-market after the FDA confirmed its Phase 3 trial for Alzheimer's drug Zervimesine.
08-13 16:55
Chardan Capital Maintains Buy on Cognition Therapeutics, Maintains $4 Price Target
Chardan Capital analyst Daniil Gataulin maintains Cognition Therapeutics (NASDAQ:CGTX) with a Buy and maintains $4 price target.
08-08 20:07
Cognition Therapeutics Presents Results From Phase 2 COG1201 SHIMMER Study Of Zervimesine In Dementia With Lewy Bodies At AAIC 2025
- Zervimesine's impact on debilitating DLB behavioral symptoms highlighted in podium presentation -- Plasma p-tau217 levels can identify Alzheimer's patients most likely to benefit from zervimesine treatment -- Plasma
07-29 19:38
Cognition Therapeutics Presents Data at AAIC Highlighting Broad Neurological Impact of Zervimesine (CT1812) in Dementia with Lewy Bodies and Alzheimer’s Disease
Cognition Therapeutics presented Phase 2 results for zervimesine in DLB and Alzheimer’s disease. In DLB, zervimesine improved neuropsychiatric symptoms like hallucinations and anxiety by 86% vs. placebo. In Alzheimer’s, plasma p-tau217 levels identified patients more likely to benefit, with zervimesine arresting cognitive decline by 129% and 91% in mild and moderate cases. Biomarkers showed reductions in neuroinflammation and neurodegeneration pr...
07-29 11:30
Cognition Therapeutics Publishes Proteomic Analysis Elucidating Zervimesine’s Protection of Neurons and Synapses in Alzheimer’s Disease
Cognition Therapeutics Inc. announced results from its Phase 2 SEQUEL study of zervimesine (CT1812), showing improvements in EEG parameters and neuroprotective effects in mild-to-moderate Alzheimer's disease patients. The study revealed reduced theta waves and increased functional connectivity, suggesting zervimesine may normalize synaptic function. Proteomics analysis linked the drug to processes involving vesicle formation and endosomal traffic...
07-21 11:30
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812) Phase 2 Study in Dementia with Lewy Bodies (DLB) will be Presented in a Podium Presentation at AAIC
Cognition Therapeutics announced positive results from the Phase 2 SHIMMER study of zervimesine in patients with dementia with Lewy bodies (DLB), showing significant improvements in behavioral, cognitive, and motor symptoms. The study, supported by an NIH grant, demonstrated that zervimesine-treated participants performed 86% better in behavioral outcomes and 91% better in cognitive fluctuations compared to placebo. Additionally, in the Phase 2 S...
07-16 11:30
Cognition Therapeutics shares are trading higher after the company completed an End-of-Phase 2 meeting with the FDA for Zervimesine in Alzheimer's disease.
Cognition Therapeutics shares are trading higher after the company completed an...
07-10 19:33
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for Zervimesine (CT1812) in Alzheimer’s Disease
Cognition Therapeutics Inc. (NASDAQ: CGTX) held an end-of-Phase 2 meeting with the FDA to review results of the Phase 2 SHINE Study for zervimesine (CT1812) and discuss Phase 3 plans for its potential approval as an Alzheimer’s disease treatment. Lisa Ricciardi, CEO, expressed confidence in the path forward after the meeting. Zervimesine, an oral drug targeting neurodegenerative diseases, aims to disrupt toxic effects of Aβ and α-synuclein protei...
07-10 11:30
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Artelo Biosciences (NASDAQ:ARTL) stock moved upwards by 171.6% to $27....
07-07 20:07
